HitGen(688222)2024-03-15 07:34Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. aims to become a world-class innovative biopharmaceutical company focused on improving human health [3][4]. - The company specializes in the discovery and optimization of small molecules and nucleic acid drugs, leveraging core technologies such as DNA-encoded libraries (DEL), fragment-based drug design (FBDD/SBDD), and targeted protein degradation (TPD) [3][4]. Key Technologies - The DEL library has over 1.2 trillion molecules, with more than 6,000 types of synthetic scaffolds, covering most core scaffolds of approved small molecule drugs and many ongoing clinical projects [4]. - The company has multiple internal drug projects at various clinical and preclinical stages, with a focus on delivering innovative drug solutions to meet unmet clinical needs globally [4]. Research and Development - The computational science team has evolved since the company's establishment in 2012, integrating artificial intelligence (AI) into drug development processes [5][6]. - Collaborations with industry partners began in 2020, including a partnership with Tencent AI Lab to develop a molecular scaffold transition algorithm [6][11]. Recent Achievements - The company has transferred over 800 compounds, with 86% classified as pioneering molecules, indicating their novelty and potential for patent applications [12]. - A recent joint publication with BioAge highlighted the discovery of novel NLRP3 inhibitors using DEL technology, which may provide new treatment methods for diseases like Alzheimer's and Parkinson's [11][12]. Market Position - Chengdu XianDao is one of the earliest companies in China to focus on small molecule oral drugs targeting IL-17A, with ongoing optimization of its second-generation products [10][12]. - The company emphasizes the importance of rational investment and long-term development in the innovative drug research sector [10][12].